I grew up watching my father teach and run a small business, which gave me curiosity, grit, and a practical instinct for turning ideas into results. Veterinary training taught me to view biology at the organism level and to value animal welfare, leading to a master’s, a PhD in pharmacology and toxicology, a pathology residency, and early research in metabolic liver disease. Moving from India to the U.S., transitioning from academia into pharma, and founding SPECCRO required risk, rapid learning, and a focus on practical translation, all guided by mentors whose influence shapes how I lead and build teams today. SPECCRO applies human‑relevant, platform‑neutral methods, combining traditional paradigms with emerging NAMs approaches for preclinical drug development, and I have been fortunate to gain hands‑on experience with real‑world applications, including developing these tools and engaging in regulatory interactions that shape their utility. By bringing rigorous science, thoughtful methods, and talent development together, we accelerate better medicines. This is the work, I love, and I am excited to keep scaling the team, the science, and the impact.
The Problem
After years leading toxicology and translational science efforts, I saw firsthand the advantages of both traditional models and emerging paradigms, and how together they can better reflect human outcomes.
The Gap
What we needed wasn’t incremental improvement but a shift—a platform built on human biology from the start, scientifically rigorous and ethically grounded. The gap is relying only on conventional paradigms; the opportunity is to learn from them and build forward with new, unconventional new approach methodologies that better reflect human outcomes.
The Vision
That’s why I founded SPECCRO: to build a platform that leverages the strengths of traditional drug-development paradigms and seamlessly blend them with innovative NAMs-driven approaches, creating a more connected, execution-ready path from strategy to translational clarity.
The Why
SPECCRO exists to bring science closer to the patient, where human biology, regulatory foresight, AI-powered technology, and translational rigor converge to redefine preclinical decision-making. We’re building a future where smarter, faster, and more ethical drug development begins with relevance, not revision.